Fundraising Fox
Eledon
3 known investors
Find your way into Eledon
Sign up to see every warm intro you have to Eledon
- Paths you didn't know you had: your email and LinkedIn already hold routes to the Eledon team. We find them for you
- 2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
- Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone
Days of research, done the moment you sign in, with every route ranked by how warm it is.
Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.
Founders & leadership
SP
Steven PerrinPresident and Chief Scientific Officer
Investors · 3
Newpath PartnersreportedBoston · $50K – $10M
How we know: the VCSheet dataset · Not right? Tell us
Funding
SEC filings, press & company announcements- Undisclosed amountprivate investment in public equity financingMay 2024
BVF Partners (lead)
Source ↗
Source: company announcements and press reports — follow each round's link for the claim.
In the news
Eledon Pharmaceuticals (ELDN) widens Q2 loss while advancing tegoprubart to Phase 3stocktitan.net · Aug 2026Frequently asked questions
- What does Eledon do?
- Eledon Pharmaceuticals is a clinical-stage biotechnology company developing immunology-based therapies, with a focus on protecting transplanted organs from rejection and treating autoimmune and neurodegenerative diseases including ALS. The company's lead candidate is tegoprubart, an anti-CD40L antibody.
- Who are Eledon's investors?
- Eledon's investors include JDRF T1D Fund, Biotechnology Value Fund, Newpath Partners.